The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Enhertu Enters PIII for 1st Line HER2-Positive Breast Cancer
Daiichi Sankyo and AstraZeneca said on June 14 that the first patient has been dosed in a global PIII study for their antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) for the first-line treatment of patients with HER2 positive metastatic breast cancer.…
To read the full story
Related Article
BUSINESS
- Opdivo-Yervoy Combo Expands Label for Colorectal Cancer in Taiwan: Ono
January 15, 2026
- UK Fund AVI Raises Stake in Wakamoto Above 10%
January 14, 2026
- Eisai Picks Up Rights to Nuvation’s Taletrectinib in Europe, Other Regions
January 14, 2026
- Ono’s Colorectal Cancer Med Braftovi Widens Label in South Korea
January 14, 2026
- Nxera Snags US$3.6 Million Early-Stage Milestone on OX2R Agonist
January 14, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…